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Abstract. 
Repeated oral azithromycin distribution targeted only to children has proven effective in reducing the ocular 
Chlamydia that causes trachoma. Here, we assess whether an enhanced coverage target of at least 90% of children is 
superior to the World Health Organization recommendation of at least 80%. Twenty-four trachoma-endemic 
communities in Matamèye, Niger, were randomized to a single day of azithromycin distribution aiming for at least 
80% coverage or up to 4 days of treatment and > 90% coverage of children under age 12. All distributions were 
biannual. Children < 5 years of age and adults > 15 years were monitored for ocular Chlamydia infection by 
polymerase chain reaction every 6 months for 36 months in children and at baseline and 36 months in adults. Ocular 
Chlamydia prevalence in children decreased from 24.9% (95% confidence interval [CI] 15.9–33.8%) to 4.4% (95% 
CI 0.6–8.2%, P < 0.001) at 36 months in the standard coverage arm and from 15.6% (95% CI 10.0–21.2%) to 3.3% 
(95% CI 1.0–5.5%; P < 0.001) in the enhanced coverage arm. Enhanced coverage reduced ocular Chlamydia 
prevalence in children more quickly over time compared with standard (P = 0.04). There was no difference between 
arms at 36 months in children (2.4% lower with enhanced coverage, 95% CI 7.7–12.5%; P = 0.60). No infection 
was detected in adults at 36 months. Increasing antibiotic coverage among children from 80% to 90% may yield 
only short term improvements for trachoma control programs. Targeting treatment to children alone may be 
sufficient for trachoma control in this setting. 
INTRODUCTION 
Annual mass azithromycin distribution is a core component of the World Health 
Organization (WHO)’s trachoma control strategy.1,2 When clinical trachoma prevalence is more 
than 10% among children less than 10 years, the WHO standard is to treat all individuals in a 
community. As part of this strategy, the WHO recommends mass azithromycin coverage of at 
least 80% in the community.3 High coverage is recommended to prevent reemergence of 
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infection in communities.4,5 However, ocular Chlamydia infection, which causes trachoma, is 
overwhelmingly found in young children.6–8 Furthermore, the duration of infection is longer at 
younger ages,9 and children have a higher bacterial load.10 Targeting antibiotics to a core group 
of children may prevent infection in untreated individuals through indirect, herd-like 
protection.5,11 Strategies that do not involve distribution to the entire community may have 
advantages by conserving resources and reducing antibiotic consumption and resistance. 
Mathematical models suggest that strategies involving targeting antibiotics to children 
require distribution of antibiotics more frequently than mass distribution to the entire 
community, with little margin for incomplete coverage.5 Empirically, biannual targeting of 
azithromycin to children has been shown to be noninferior to annual distribution to all 
individuals in a community for trachoma control.12 Furthermore, treatment of children leads to 
reduced ocular Chlamydia prevalence among untreated adults.11,12 Alternative antibiotic 
strategies for trachoma control, beyond annual mass azithromycin distribution, thus include 
strategies that target antibiotics to core groups of children. 
Here, we assess two different coverage targets for biannual azithromycin distribution targeted 
to children aged 6 months to 12 years. We compare distribution on a single day aimed to 
approximate the 80% recommended by the WHO (standard coverage target) versus at least 90% 
(enhanced coverage target) to determine if higher antibiotic coverage leads to greater decreases 
in ocular Chlamydia prevalence. 
METHODS 
Study setting and design. 
The Partnership for the Rapid Elimination of Trachoma (PRET) study was a collection of 
separate cluster-randomized trials designed to evaluate mass antibiotic distribution strategies for 
trachoma control in the Gambia, Tanzania, and Niger (NCT00792922).4,12–14 The Niger trial was 
the only one of the three trials to evaluate azithromycin distribution targeted specifically to 
children. The Niger trial enrolled participants in the Matamèye District, Zinder Region, Niger, 
between May 2010 and August 2013 into one of four arms designed to assess the effects of 
standard (> 80%) versus enhanced (> 90%) azithromycin coverage and to compare annual 
treatment of all individuals versus biannual treatment of children aged 12 years and younger. 
Here, we report a prespecified analysis of outcomes comparing standard versus enhanced 
biannual treatment to children aged 12 years and younger. Twenty-four grappes (smallest 
government health unit; henceforth, “community”) from six Centers de Santé Intégrées (CSI) 
were included in this analysis. Complete methods for the trial have been previously reported.12 
Ethical approval for the trial was obtained from the Committee for Human Research at the 
University of California, San Francisco, and the Comité d’Ethique du Niger (Ethical Committee 
of Niger). The study was registered at ClinicalTrials.gov (NCT00792922) and implemented in 
accordance with the Declaration of Helsinki. Verbal informed consent was obtained from each 
local community chief before randomization and each individual or guardian before examination. 
Given low reported literacy rates in the area, both institutional review boards approved the verbal 
informed consent procedure. 
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Community eligibility and randomization. 
Eligible communities had a population between 250 and 600 at the most recent government 
census. Communities with less than 10% prevalence of trachomatous inflammation-
follicular/trachomatous inflammation-intense (TF/TI) were excluded. To measure baseline TF/TI 
prevalence, before the first mass antibiotic treatment, a door-to-door census was conducted in 
eight communities per CSI. A random sample of 100 children aged 0–60 months were assessed 
for active trachoma according to the WHO simplified grading system.8,15 If a given community 
had less than 10% TF/TI prevalence, another community in the CSI was censused, and trachoma 
prevalence was assessed, until each CSI had eight enrolled communities. 
After inclusion, communities were randomized by stratified block randomization within each 
CSI by high or low TF/TI prevalence in children. Communities above the median trachoma 
prevalence in a given CSI were considered to be “high” prevalence, and those below the median 
were considered to be “low” prevalence. The random allocation sequence was generated by TCP 
using the statistical package R (version 2.12; R Foundation for Statistical Computing, Vienna, 
Austria; www.r-project.org). 
Study intervention. 
All communities in the biannual arms of PRET-Niger received six rounds of mass 
azithromycin distribution. Azithromycin was distributed via a door-to-door program. Study 
participants aged 6 months to 12 years were offered treatment. Children under 6 months of age 
and those known to be allergic to macrolides were offered topical tetracycline ointment (1%) to 
be applied to both eyes twice a day for 6 weeks. In the standard arm, antibiotic distributions were 
performed on a single day, aiming for an antibiotic coverage target (defined as the proportion of 
the targeted population that was treated) of 80% or greater. In the enhanced arm coverage, up to 
three follow-up visits were performed in an attempt to achieve coverage of 90% or greater. 
Individuals more than 12 years of age were not treated. Communities had received some 
education on face washing and the importance of hygiene, but no specific interventions (e.g., 
latrinization or program-related well construction) were given as part of the study. At the time of 
the study, annual mass azithromycin distribution according to WHO guidelines was the standard 
for trachoma control, distributed via a distribution point supplemented by door-to-door mop-up. 
Outcome assessments. 
A census was conducted in each community annually. For each 6-month data collection time 
point, 100 children aged 0–5 years were randomly selected (or all children if there were fewer 
than 100 in a given community) from the most recent census before the data collection point. 
Children were examined biannually at baseline and months 6, 12, 18, 24, 30, and 36. A random 
sample of 40 individuals over the age of 15 per community was swabbed at baseline and 36 
months. Clinical examination was performed in children according to the WHO simplified 
grading system as previously described.8,15 Examiners were not made aware of the community’s 
treatment allocation and were separate personnel from treatment teams. The right and left upper 
tarsal conjunctiva was everted, and the right conjunctiva was swabbed. Swabs were collected 
without media, transported to UCSF and stored at −80°C. Swabs were pooled within a 
community and age groups into pools of five plus a remainder pool and then processed for 
Chlamydia with Amplicor polymerase chain reaction testing. The prevalence of ocular 
Chlamydia was estimated from the pooled results as previously described.16 In communities 
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where more than 80% of pools were positive, all samples were processed individually to more 
accurately estimate community prevalence. All laboratory personnel were masked to the 
intervention arm. 
Sample size. 
In the parent trial, we estimated a sample size of 48 communities (12 per arm) would yield 
greater than 80% power to detect a 6% absolute difference in ocular Chlamydia infection in 
children. The current report includes only the communities randomized to the two coverage 
targets for biannual treatment of children. 
Statistical methods. 
As per our prespecified analysis plan, all analyses used a square root transformation of ocular 
Chlamydia infection prevalence and included adjustment for baseline prevalence. Reduction in 
ocular Chlamydia prevalence between baseline and at 36 months was analyzed using a paired t 
test. For the primary analysis, we used a linear regression model to compare the 36-month square 
root transformed prevalence of ocular Chlamydia in children aged 0–5 years between 
communities randomized to enhanced coverage compared with standard coverage, adjusting for 
baseline prevalence. As a prespecified secondary analysis to assess the rate of change in ocular 
Chlamydia prevalence over time, we used a mixed effects model with square root transformed 
ocular Chlamydia prevalence at each time point (months 0, 6, 12, 18, 24, 30, and 36), with 
treatment arm and a time point by arm interaction term as fixed effects and a random effect for 
community. A similar analytic strategy was used for determining the effect of treatment coverage 
on the prevalence of TF. All P values were calculated using an exact permutation test. All 
analyses were conducted in R (version 3.3.1, The R Foundation for Statistical Computing, 
Vienna, Austria) at the community level. 
RESULTS 
At baseline, the 12 communities randomized to standard coverage had a mean of 111 (range 
41–176) children aged 0 to 5 years treated, and the 12 communities randomized to enhanced 
coverage had a mean of 126 (range 71–276) treated (Figure 1). Baseline characteristics, 
including age and gender and prevalence of TF and infection, were well balanced at baseline 
(Table 1). Antibiotic coverage among children aged 0–5 ranged from 75.8% (95% confidence 
interval [CI] 71.6–80.1%) to 84.3% (95% CI 80.1– 88.6%) in the standard coverage arm and 
from 91.1% (95% CI 88.1–94.1%) to 94.2% (95% CI 92.1–96.4%) in the enhanced coverage arm 
(Table 2). 
Ocular Chlamydia prevalence was reduced from 24.9% (95% CI 15.9–33.8%) to 4.4% (95% 
CI 0.6–8.2%, P < 0.001; Figure 2) in the standard coverage arm and from 15.6% (95% CI 10.0–
21.2%) at baseline to 3.3% (95% CI 1.0–5.5%; P < 0.001) at 36 months in the enhanced 
coverage arm. In a model adjusting for ocular Chlamydia prevalence at baseline, there was no 
difference in ocular Chlamydia prevalence at 36 months in communities randomized to the 
standard versus enhanced coverage arm (mean difference 2.4% in the enhanced versus standard 
arm at 36 months, 95% CI 7.7–12.5%; P = 0.60). In a repeated measures model, ocular 
Chlamydia prevalence reduced more quickly over time in the enhanced arm compared with that 
in the standard arm (P = 0.04). 
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In adults aged 15 years and older, ocular Chlamydia prevalence was 1.8% (95% CI 0.04–
3.6%) in the standard arm and 0.5% (95% CI 0–1.2%) in the enhanced arm at baseline. At 36 
months, there was no infection detected in adults in any community, and no difference in 
infection at 36 months between the two arms. 
TF prevalence was reduced from 24.7% (95% CI 16.4–32.9%) to 10.1% (95% CI 3.7–16.5%; 
P = 0.001; Figure 3) in the standard coverage arm and from 23.9% (95% CI 16.3–31.5%) at 
baseline to 5.4% (95% CI 2.9–7.9%; P = 0.0001) at 36 months in the enhanced coverage arm. 
Adjusting for baseline, there was no difference between TF prevalence in the standard compared 
with the enhanced arm (mean difference −4.6% in the enhanced versus the standard arm at 36 
months, 95% CI 11.1–1.9%; P = 0.20). In a repeated measures model, there was no evidence of 
differential change over time in TF prevalence between the enhanced and standard arms (P = 
0.19). 
DISCUSSION 
In this study, we demonstrate that achieving higher antibiotic treatment coverage in 
communities treating children biannually may have resulted in a faster decrease in ocular 
Chlamydia prevalence. However, after 36 months, the prevalence was not significantly different 
from standard coverage. In this mesoendemic setting in Niger, for biannual distribution of 
azithromycin to children, increasing antibiotic coverage above 80% may yield only marginal 
returns for trachoma control programs. Consistent with results from other mesoendemic regions, 
strategies targeting treatment only to children appear to be effective for reducing the prevalence 
of ocular Chlamydia.17 
The WHO recommends annual mass azithromycin distribution for 3–5 years followed by an 
impact assessment in communities with clinical trachoma prevalence above 10% in children 
younger than 10 years of age. If the assessment shows control has not been achieved then annual 
distributions would continue. In the present study, biannual distribution with approximately 80% 
coverage did not reduce TF prevalence below 10% in children younger than 5 years of age. 
Biannual treatment strategies involve greater costs and are more logistically intense than annual 
treatment strategies. However, treatment of children is considered easier than that of adults.17 In 
a previous analysis, we demonstrated that biannual treatment of children alone was noninferior to 
annual mass azithromycin distribution.12 Although we did not compare biannual with annual 
distribution in the present analysis, these results may indicate that in some regions treatment may 
be required for a longer duration to reduce TF prevalence below 10%. 
With repeated antibiotic distributions, perfect coverage of all individuals in a community 
may not be required for elimination, as untreated children may receive indirect protection from 
those treated. Children form a core group for infection in mathematical models.5 However, 
models suggest that increasing antibiotic coverage should result in more rapid elimination.5 
Previous work from the parent study of this analysis found that biannual treatment of children 
yielded comparable results to annual treatment of all adults in the community and that infection 
in adults reduced similarly in communities where only children were treated and where all 
individuals were treated.12 Previous evidence from a hyperendemic region of Ethiopia 
demonstrated a herd effect for trachoma. With quarterly treatment of children younger than 10 
years of age, ocular Chlamydia prevalence was reduced by approximately half in adults, even 
though adults themselves had not received treatment.11 In Nepal, mass treatment of children was 
found to be cost effective compared with mass treatment of the entire community.18 The present 
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results add to the evidence that treatment of a subgroup of the population may be sufficient for 
trachoma control among children and adults. However, achieving higher coverage of antibiotic 
treatment is both costlier and more logistically challenging. These results indicate that even with 
treatment targeted only to children, imperfect treatment coverage will not jeopardize trachoma 
control programs. 
Treatment targeted only to children younger than the age of 12 years resulted in no infection 
in adults aged 15 and older by 36 months. Previous work in Ethiopia has demonstrated that 
treatment of children in communities leads to decreases in ocular Chlamydia prevalence in adults 
via herd-like protection.11,19 In the present study, infection prevalence was low at baseline. 
Whereas it is possible that over the 3-year period infection would have disappeared in the 
community in the absence of treatment of children, these results indicate that treatment of adults 
may not be required for trachoma control programs. 
There may be additional benefits to limiting antibiotic distributions in communities. Mass 
azithromycin distribution selects for macrolide resistance in Streptococcus pneumoniae isolates 
from Ethiopian children.20 Although this selection pressure is removed and the prevalence of 
resistance decreases when antibiotic distributions are discontinued,21 minimizing the amount of 
antibiotic distributed may help minimize the extent of antibiotic resistance. Strategies that target 
only children and have lower coverage targets reduce antibiotic consumption, potentially 
resulting in less antibiotic resistance. 
The results of this study must be evaluated in the context of several limitations. Outcomes, 
including ocular Chlamydia prevalence and TF, were measured in a random sample of children, 
and thus elimination in a given community cannot be definitively determined. Thus, an observed 
prevalence estimate of 0% does not guarantee elimination, and infection could return over time 
after cessation of treatment. In addition, this study took place in a mesoendemic region of Niger, 
and as such, these results may not generalize to regions with differing endemicity. Although 
clinical examiners were not made aware of the intervention arm of communities, it is possible 
they could have asked community members about the treatment that had occurred in a given 
community, which could have compromised masking of clinical examination. However, the 
primary outcome was ocular Chlamydia prevalence, and all laboratory personnel were fully 
masked (Table 3). 
Although azithromycin distribution programs have been extremely effective in reducing 
trachoma prevalence worldwide, trachoma control has remained a challenge in some severely 
affected districts. Alternative strategies, such as targeting core groups of children, increasing the 
frequency of distributions, and expanding antibiotic coverage, have been considered in these 
areas. The results of this study indicate that increasing antibiotic coverage above the WHO 
recommendation may not be necessary to effectively reduce trachoma prevalence in 
mesoendemic settings similar to that of this community-randomized trial. 
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FIGURE 1. Flow diagram of study communities. 
FIGURE 2. Prevalence of ocular Chlamydia infection in children aged 0–5 years in communities randomized to 
standard (A) or enhanced (B) coverage. All communities received biannual mass azithromycin treatment in children 
less than 12 years of age. 
FIGURE 3. Prevalence of trachomatous inflammation in children aged 0–5 years in communities randomized to 
standard (A) or enhanced (B) coverage. All communities received biannual mass azithromycin treatment in children 
less than 12 years of age. 
TABLE 1 
Baseline characteristics of study communities 
 Standard coverage Enhanced coverage 
Number of communities 12 12 
Total number of individuals per community (range) 497 (325–670) 458 (310–569) 
Mean number of children aged 0–5 years per community 
(range) 143 (60–236) 144 (77–290) 
Proportion of female participants (95% CI) 51.6% (50.1–53.1%) 49.9% (48.1–51.6%) 
Prevalence of ocular Chlamydia in children aged 0–5 years 
(95% CI) 24.9 (15.9–33.8) 15.6 (10.0–21.1) 
Prevalence of TF in children aged 0–5 years (95% CI) 24.7 (16.4–32.9) 23.9 (16.3–31.5) 
CI = confidence interval; TF = trachomatous inflammation–follicular. 
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TABLE 2 
Mean treatment coverage among children 0–5 years during mass antibiotic distributions by study visit 
 Standard coverage Enhanced coverage 
0 months (95% CI) 80.8% (76.4–85.1%) 94.2% (92.1–96.4%) 
6 months (95% CI) 78.6% (74.6–82.6%) 92.1% (89.1–95.2%) 
12 months (95% CI) 81.1% (78.3–84.0%) 93.6% (91.7–95.5%) 
18 months (95% CI) 82.2% (77.2–87.1%) 92.9% (88.4–97.3%) 
24 months (95% CI) 84.3% (80.1–88.6%) 91.4% (89.7–93.1%) 
30 months (95% CI) 78.2% (74.0–82.4%) 91.2% (87.9–94.4%) 
36 months (95% CI) 75.8% (71.6–80.1%) 91.1% (88.1–94.1%) 
CI = confidence interval. 
Page 10 of 14 
TABLE 3 
Longitudinal prevalence of ocular Chlamydia among a random sample of 0- to 5-year-old children 
 Prevalence of ocular Chlamydia, 0- to 5-year-old children 
Communit
y 
Month 0 Month 6 Month 12 Month 18 Month 24 Month 30 Month 36 
Standard coverage 
1 7.8% (8/103) 5.7% (6/105) 5.9% (6/102) 1.9% (2/104) 4.9% (5/103) 13.3
% 
(15/113
) 
6.1% (6/99) 
2 26.0
% 
(13/50) 18.9
% 
(10/53) 7.0% (3/43) 4.3% (2/47) 8.2% (4/49) 11.5
% 
(6/52) 1.8% (1/55) 
3 39.0
% 
(39/100
) 
8.7% (9/104) 5.0% (5/101) 8.8% (9/102) 23.5
% 
(23/98) 13.9
% 
(10/72) 20.8
% 
(16/77) 
4 33.8
% 
(27/80) 23.0
% 
(17/74) 13.4
% 
(9/67) 13.5
% 
(10/74) 9.4% (6/64) 7.9% (5/63) 2.9% (1/35) 
5 40.3
% 
(27/67) 14.5
% 
(9/62) 2.1% (1/48) 0 (0/49) 2.4% (1/42) 2.3% (1/44) 4.0% (2/50) 
6 9.3% (9/97) 8.8% (7/80) 2.5% (1/40) 0 (0/51) 3.2% (1/31) 0 (0/23) 0 (0/11) 
7 41.7
% 
(43/103
) 
15.8
% 
(16/101
) 
15.2
% 
(16/105
) 
7.6% (8/105) 15.2
% 
(17/112
) 
2.3% (2/86) 1.6% (1/64) 
8 6.9% (6/87) 9.6% (8/83) 4.1% (3/73) 13.0
% 
(9/69) 7.0% (6/86) 1.2% (1/86) 0 (0/73) 
9 38.8
% 
(40/103
) 
15.4
% 
(16/104
) 
5.0% (5/100) 12.5
% 
(14/112
) 
11.4
% 
(12/105
) 
15.7
% 
(16/102
) 
10.5
% 
(11/105
) 
10 15.7
% 
(16/102
) 
6.3% (6/95) 4.2% (4/95) 1.1% (1/92) 0 (0/120) 0 (0/108) 0 (0/89) 
11 28.8
% 
(30/104
) 
11.7
% 
(12/103
) 
7.8% (8/103) 2.9% (3/102) 2.7% (3/113) 7.8% (8/102) 4.3% (4/94) 
12 10.2
% 
(18/177
) 
3.6% (6/165) 2.4% (4/165) 15.5
% 
(24/155
) 
15.0
% 
(21/140
) 
0.8% (1/129) 0.9% (1/108) 
Enhanced coverage 
13 22.5
% 
(23/102
) 
7.8% (8/102) 3.9% (4/102) 4.8% (5/105) 4.8% (5/105) 4.0% (4/100) 8.3% (8/96) 
14 10.3
% 
(6/58) 0 (0/76) 2.9% (2/68) 0 (0/72) 0 (0/62) 0 (0/56) 0 (0/61) 
15 15.8
% 
(15/95) 1.1% (1/93) 0 (0/93) 1.1% (1/87) 1.2% (1/81) 1.2% (1/82) 0 (0/78) 
16 18.5 (20/108 3.0% (3/100) 1.0% (1/101) 0 (0/104) 1.0% (1/100) 2.7% (3/113) 2.2% (2/89) 
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% ) 
17 4.2% (3/72) 0 (0/69) 0 (0/53) 0 (0/43) 0 (0/55) 0 (0/38) 6.3% (2/32) 
18 13.7
% 
(14/102
) 
1.0% (1/105) 0 (0/91) 1.0% (1/103) 1.0% (1/100) 2.0% (2/102) 3.0% (3/99) 
19 10.7
% 
(8/75) 4.2% (3/72) 0 (0/66) 0 (0/78) 1.3% (1/75) 0 (0/70) 0 (0/65) 
20 34.9
% 
(37/106
) 
13.1
% 
(14/107
) 
3.7% (4/107) 1.0% (1/103) 1.0% (1/99) 14.6
% 
(14/96) 7.1% (6/85) 
21 13.8
% 
(9/65) 1.5% (1/66) 4.0% (2/50) 0 (0/54) 0 (0/68) 0 (0/51) 0 (0/50) 
22 2.8% (3/109) 0 (0/98) 0 (0/103) 0 (0/107) 0 (0/96) 0 (0/107) 0 (0/104) 
23 15.5
% 
(16/103
) 
3.9% (4/104) 4.0% (4/101) 8.3% (9/108) 7.7% (8/104) 6.6% (5/76) 2.8% (2/72) 
24 24.0
% 
(25/104
) 
4.9% (5/102) 4.6% (5/109) 1.8% (2/110) 8.4% (9/107) 28.9
% 
(26/90) 9.4% (9/96) 
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Figure 1 
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Figure 2 
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Figure 3 
 
 
 
